

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human PLA2G2A in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human PLA2G1B, G2A, or G7 is observed.
Source	Monoclonal Mouse IgG _{2B} Clone # 620501
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant human PLA2G2A Asn21-Cys144 Accession # P14555
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunoprecipitation	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Phospholipase A2 Group IIA (PLA2G2A) is a 17 kDa member of the phospholipase A2 family of enzymes that hydrolyzes the *sn*-2 ester bond of phospholipids. Human PLA2G2A is synthesized as a 144 amino acid (aa) precursor that contains a 20 aa signal sequence and a 124 aa mature chain. Mature human PLA2G2A shares 72%, 68%, and 60% aa sequence identity with mature rat, mouse, and bovine PLA2G2A, respectively. PLA2G2A is a calcium dependent phospholipase expressed in many cell types associated with inflammation, including platelets, neutrophils, and mast cells. Most secretory PLA2s are stored in cytoplasmic granules and are released into the extracellular environment on appropriate cell activation. Thus, they are present at higher concentrations in the plasma and biologic fluids of patients with systemic inflammatory, autoimmune, or allergic diseases.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.